TREM2 in Parkinson's Disease — A Cross-Disease Therapeutic Opportunity describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a receptor predominantly expressed on microglia in the brain. Variants in the TREM2 gene represent one of the strongest genetic risk factors for Alzheimer's Disease, with loss-of-function variants increasing AD risk by 2-4x[1]. Despite extensive research in AD, the role of TREM2 in Parkinson's Disease remains surprisingly underexplored — a significant gap given the shared neuroinflammatory pathophysiology between these neurodegenerative disorders.
A crucial recent finding demonstrates that TREM2 is significantly upregulated in the substantia nigra of PD patients compared to age-matched controls[2]. This upregulation is particularly pronounced in microglia surrounding dopaminergic neurons, suggesting a compensatory response to ongoing neurodegeneration. Single-cell transcriptomics has revealed a distinct population of TREM2-expressing microglia that display unique gene signatures related to phagocytosis and lipid metabolism[3].
The anatomical distribution of TREM2+ microglia in PD brain shows a characteristic pattern: highest density in regions with maximal dopaminergic neuron loss, including the substantia nigra pars compacta and striatum. This spatial correlation strongly implicates TREM2 in the disease process[4]. Importantly, the level of TREM2 expression correlates with disease duration and severity, suggesting that TREM2 upregulation may represent both a pathological marker and a potential therapeutic target.
Parkinson's Disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, accompanied by Lewy bodies composed of misfolded alpha-synuclein. Emerging evidence demonstrates that microglia — the brain's innate immune cells — play a critical role in both clearing toxic protein aggregates and contributing to neurotoxicity through chronic inflammation[5].
Microglia in Parkinson's Disease exhibit:
Single-cell RNA sequencing has revealed remarkable heterogeneity in microglial populations in PD brain. At least four distinct microglial states can be identified:
Homeostatic microglia: Characterized by expression of P2RY12, CX3CR1, and TREM2. These cells represent the resting population and decrease in PD.
Disease-associated microglia (DAM): Upregulate TREM2, APOE, and LPL. These cells attempt to clear pathology but become dysfunctional over time.
Inflammatory microglia: Express high levels of IL1B, TNF, and other pro-inflammatory cytokines. These cells drive neurotoxicity.
Lipid-loaded microglia: Accumulate lipid droplets and show impaired phagocytic function. TREM2 dysfunction may contribute to this phenotype.
The balance between these microglial states determines whether the neuroinflammatory response is protective or harmful. TREM2 plays a critical role in this balance, promoting the DAM phenotype while suppressing inflammatory activation.
TREM2 serves as a critical regulator of microglial function:
Phagocytic Clearance: TREM2 signaling enables microglia to clear amyloid plaques in AD[6]. By analogy, TREM2 activation could enhance clearance of alpha-synuclein aggregates in PD.
Neuroinflammation Modulation: TREM2 promotes a disease-associated microglia (DAM) phenotype that is protective rather than inflammatory[7]. Therapeutic modulation could shift microglia toward a neuroprotective state.
Metabolic Reprogramming: TREM2 signaling supports microglial metabolic fitness, which may be particularly relevant given mitochondrial dysfunction in PD.
Genetic Evidence: While TREM2 variants are most strongly associated with AD, genome-wide association studies (GWAS) have identified shared microglial pathways between AD and PD[8]. The same microglial networks implicated in AD may contribute to PD pathogenesis.
While TREM2 genetic variants are most strongly associated with Alzheimer's disease, emerging evidence suggests that TREM2 may also influence Parkinson's disease risk. A comprehensive study in European populations identified specific TREM2 variants that show nominal association with PD susceptibility[9]. Notably, the well-known R47H loss-of-function variant (rs75932628) shows a trend toward increased PD risk, though the effect size is smaller than in AD.
In Chinese populations, specific TREM2 variants have been associated with earlier age of onset and more rapid disease progression[10]. The genetic landscape of TREM2 in PD appears to differ between ancestral groups, highlighting the importance of population-specific studies. These findings suggest that TREM2 genetic screening could potentially identify subsets of PD patients who might benefit most from TREM2-targeted interventions.
A critical breakthrough in understanding TREM2's role in PD comes from studies demonstrating the direct interaction between alpha-synuclein pathology and TREM2 signaling. TREM2 functions as a scavenger receptor for alpha-synuclein fibrils, facilitating microglial uptake and clearance[11]. When TREM2 is deficient, this clearance mechanism is impaired, leading to increased extracellular accumulation of toxic alpha-synuclein species.
TREM2-deficient mice in alpha-synuclein overexpression models exhibit dramatically exacerbated pathology compared to controls[12]. Specifically, these animals show:
The mechanism involves TREM2-dependent signaling cascades that regulate microglial phagocytosis. Upon binding to alpha-synuclein fibrils, TREM2 activates downstream pathways including PLCgamma2, which is essential for the cytoskeletal reorganization required for phagocytosis[13]. This signaling axis represents a promising therapeutic target.
TREM2 engagement triggers a complex intracellular signaling network in microglia. Upon ligand binding, TREM2 recruits the adaptor protein DAP12 (TYROBP), which initiates downstream cascades including:
In PD, TREM2-dependent signaling appears to be dysregulated, contributing to both impaired clearance and excessive inflammation. The balance between these functions may determine whether TREM2 activation is protective or harmful.
TREM2 is closely linked to microglial lipid metabolism. TREM2 recognizes lipid-associated ligands, including apolipoprotein E (ApoE), which is highly relevant given the known association between APOE variants and PD risk. TREM2 signaling modulates microglial lipid droplet formation and cholesterol efflux[15]. In the context of alpha-synuclein pathology, proper lipid metabolism is essential for efficient protein clearance, as lipids serve as co-factors for alpha-synuclein aggregation and removal.
TREM2-deficient microglia exhibit impaired lipid metabolism, leading to accumulation of intracellular lipids that paradoxically both reduces phagocytic capacity and increases pro-inflammatory signaling. This metabolic dysfunction creates a vicious cycle in PD where impaired clearance and heightened inflammation reinforce each other.
Soluble TREM2 (sTREM2) is generated by alternative splicing or proteolytic cleavage of membrane-bound TREM2. CSF sTREM2 levels reflect the rate of TREM2 expression and processing in the brain, making it a potentially valuable biomarker for microglial activation in PD.
Longitudinal studies have demonstrated that CSF sTREM2 levels correlate with disease progression in PD[16]. Patients with higher baseline sTREM2 show more rapid decline on both motor and cognitive measures over follow-up periods of 2-3 years. This association suggests that sTREM2 could serve as a prognostic biomarker for identifying patients at risk of rapid progression.
In direct comparisons with AD, CSF sTREM2 patterns differ between the two diseases, with PD patients showing a characteristic pattern of early elevation that stabilizes over time, in contrast to the progressive increases seen in AD[17]. These distinct trajectories may reflect different underlying biology of microglial activation in these conditions.
Peripheral measures of TREM2 are more challenging to interpret due to contributions from peripheral immune cells. However, emerging evidence suggests that circulating sTREM2 may correlate with CNS TREM2 activity in PD, particularly when assessed in combination with other neuroinflammatory markers.
sTREM2 (soluble TREM2) is being actively investigated as a fluid biomarker for microglial activation in neurodegeneration. Elevated sTREM2 in cerebrospinal fluid correlates with disease progression in AD, and similar biomarker approaches could be applied to PD[18].
No TREM2-targeted therapies have reached clinical testing in PD specifically. However, TREM2 agonist therapies are in development for AD, and the translational path to PD could proceed rapidly:
| Therapeutic Approach | AD Status | PD Translation Potential |
|---|---|---|
| Monoclonal antibodies (anti-TREM2) | Phase 2 trials | High — similar mechanism |
| Small molecule TREM2 activators | Preclinical | Moderate — need brain penetration |
| Gene therapy (TREM2 overexpression) | Preclinical | Moderate — safety concerns |
| TREM2-independent microglial modulators | Research | High — broader applicability |
Given the biological rationale for TREM2 activation in PD, several therapeutic modalities are being explored. TREM2 agonist antibodies have shown promise in AD models and are advancing through clinical development. These same agents could potentially be repurposed for PD, particularly given the shared microglial pathophysiology.
A novel TREM2 agonist has demonstrated efficacy in the MPTP mouse model of PD, significantly attenuating dopaminergic neuron loss and improving motor function[19]. The mechanism involves activation of the TREM2-DAP12 signaling axis, leading to enhanced microglial phagocytosis of alpha-synuclein and reduced neuroinflammation. This proof-of-concept study supports further development of TREM2 agonists for PD.
An innovative approach involves TREM2-targeted nanobodies, which offer advantages over traditional antibodies including smaller size, better brain penetration, and potentially lower immunogenicity. TREM2-specific nanobodies have shown efficacy in PD models, promoting microglial clearance of alpha-synuclein aggregates and reducing neuronal loss[20]. This approach represents a promising new modality for TREM2-targeted therapy.
Given the complexity of PD pathophysiology, combination approaches targeting both protein clearance and neuroinflammation may be most effective. TREM2 modulation could be combined with:
The interaction between TREM2 and the complement system is particularly relevant, as complement proteins serve as opsonins for phagocytic clearance and may be dysregulated in synucleinopathy[21].
Repurposing TREM2 Agonists: TREM2-targeting therapeutics in development for AD could be rapidly evaluated in PD models and clinical trials.
Biomarker Development: Implementing sTREM2 as a biomarker for patient stratification and target engagement in PD clinical trials.
Combination Approaches: TREM2 modulation combined with alpha-synuclein-targeted approaches could address both protein clearance and neuroinflammation.
Optimal patient selection for TREM2-targeted trials will be critical. Considerations include:
Several challenges must be addressed for successful TREM2-targeted therapy in PD:
The development of TREM2-targeted therapies for PD carries significant implications:
| Feature | Alzheimer's Disease | Parkinson's Disease |
|---|---|---|
| TREM2 genetic association | Strong (OR 2-4x) | Not established |
| TREM2 therapeutics | In clinical trials | None |
| Protein pathology | Amyloid-beta, tau | Alpha-synuclein |
| Microglial involvement | Well-characterized | Emerging |
| Biomarker (sTREM2) | Validated | Exploratory |
The lack of TREM2 research in PD represents a significant missed opportunity. Given the strong biological rationale and the availability of TREM2-targeted therapeutics from AD research, cross-disease translation should be prioritized.
TREM2 knockout mice have been extensively characterized in PD models. In the MPTP model of dopaminergic toxicity, TREM2 deficiency results in:
These findings demonstrate that TREM2 is required for proper microglial responses to dopaminergic neuron injury. The mechanism involves both reduced phagocytic clearance of cellular debris and altered inflammatory phenotype.
Conversely, TREM2 overexpression protects against dopaminergic neurodegeneration. Transgenic mice with neuronal TREM2 expression show:
These protective effects are mediated through microglial TREM2 signaling, as conditional knockout of TREM2 in microglia abolishes the protective phenotype. The findings support therapeutic targeting of TREM2 in PD.
TREM2 dysfunction may be particularly relevant in Dementia with Lewy Bodies (DLB), which shares features of both AD and PD. Studies in DLB brain tissue reveal elevated TREM2 expression in regions with dense Lewy body pathology, similar to PD but with additional amyloid co-pathology. The presence of both alpha-synuclein and amyloid pathology may create particular demand for TREM2-mediated clearance mechanisms.
Multiple System Atrophy (MSA) represents another synucleinopathy where TREM2 may play a role. However, the pattern of TREM2 dysregulation in MSA differs from PD, with more pronounced microglial activation and different temporal patterns. This suggests that TREM2-targeted approaches may need to be tailored to specific synucleinopathy subtypes.
An important frontier is understanding TREM2 in prodromal PD, before overt motor symptoms develop. Studies in individuals with REM sleep behavior disorder (RBD), a strong prodromal marker, show intermediate levels of CSF sTREM2 between healthy controls and established PD patients. This suggests that TREM2 dysregulation begins early in the disease process and progresses with disease severity.
Early intervention with TREM2-targeted approaches could potentially modify disease progression if initiated during the prodromal phase. However, this requires development of biomarkers capable of identifying individuals likely to convert from prodromal to clinically manifest PD.
Emerging evidence indicates that TREM2 expression and function may differ between males and females, with implications for PD. Studies show that:
These differences highlight the importance of including both sexes in clinical studies of TREM2-targeted therapies and suggest that sex-stratified approaches may be warranted.
Despite recent progress, several key questions remain:
The effect of TREM2 on PD risk may be modulated by environmental exposures. For example:
Understanding these interactions could inform personalized therapeutic approaches.
Given the central role of mitochondrial dysfunction in PD, the intersection between TREM2 and mitochondrial quality control is an important emerging area. TREM2 signaling influences mitophagy through multiple mechanisms:
In PD models, TREM2 deficiency exacerbates mitochondrial dysfunction, while TREM2 activation protects against mitochondrial toxins. This suggests that mitochondrial quality control is a key mediator of TREM2's neuroprotective effects.
Guerreiro R, et al. TREM2 variants in Alzheimer's disease. New England Journal of Medicine. 2013. ↩︎
Ulsetta R, et al. TREM2 expression and signaling in Parkinson's disease brain. Acta Neuropathologica Communications. 2023. ↩︎
Zhang L, et al. Single-cell analysis of TREM2-expressing microglia in Parkinson's disease brain. Nature Communications. 2024. ↩︎
Catala M, et al. " Microglial TREM2 in Lewy body diseases: a comparative study". Acta Neuropathologica. 2024. ↩︎
Stojkovska I, et al. 'Microglia in Parkinson''s disease: role of TREM2'. Journal of Parkinson's Disease. 2018. ↩︎
Wang Y, et al. TREM2 mediates microglial amyloid-beta phagocytosis. Journal of Experimental Medicine. 2015. ↩︎
Deczkowska A, et al. 'Disease-associated microglia: A universal immune sensor of neurodegeneration'. Cell. 2018. ↩︎
Hansen DV, et al. Microglia state in neurodegeneration. Neuron. 2018. ↩︎
Christensen A, et al. TREM2 genetic variants and Parkinson's disease risk in European populations. Brain. 2024. ↩︎
Jiang T, et al. TREM2 rs75932628 variant and Parkinson's disease in Chinese population. Journal of Neurology Neurosurgery and Psychiatry. 2024. ↩︎
Huang Y, et al. TREM2 promotes microglial clearance of alpha-synuclein. Brain. 2020. ↩︎ ↩︎
Li Q, et al. TREM2 deficiency exacerbates alpha-synuclein pathology and behavioral deficits. Cell Reports. 2023. ↩︎
Engler A, et al. TREM2-PLCgamma2 signaling pathway in microglial activation. EMBO Reports. 2023. ↩︎
Bose S, et al. TREM2 modulates calcium signaling in primary microglia. Cell Calcium. 2021. ↩︎
Masliah E, et al. " TREM2 and lipid metabolism in microglia: implications for alpha-synuclein clearance". Nature Neuroscience. 2023. ↩︎
Schwarting J, et al. CSF sTREM2 levels correlate with disease progression in Parkinson's disease. Movement Disorders. 2023. ↩︎
Zhao Y, et al. Soluble TREM2 in cerebrospinal fluid as a biomarker in Parkinson's disease. Neurology. 2024. ↩︎
Ewers M, et al. Increased soluble TREM2 as a biomarker of treatment response in Alzheimer's disease. EMBO Molecular Medicine. 2020. ↩︎
Zhou Y, et al. TREM2 agonist attenuates dopaminergic neuron loss in MPTP model of PD. Neurobiology of Disease. 2024. ↩︎
Xu Y, et al. TREM2-targeted nanobody therapy for Parkinson's disease models. Advanced Science. 2024. ↩︎
Tang Y, et al. TREM2 and complement system interaction in synucleinopathy. Journal of Immunology. 2024. ↩︎
Simon M, et al. TREM2 deficiency results in reduced microglia numbers in substantia nigra. Glia. 2019. ↩︎